Pharmaceutical

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Conference call begins at 10:00 a.m. Eastern time on Thursday, May 16, 2024 WOBURN, MA / ACCESSWIRE / May 15,…

7 months ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023Q3 2024 adjusted EBITDA 1 improved by $7.0 million…

7 months ago

Lynx.MD Partners with New York Gastroenterology Associates to Enhance Gastrointestinal Research Efforts

Strategic Partnership Reveals Untapped Insights in Gastroenterology Data for Research Advancement PALO ALTO, CA / ACCESSWIRE / May 15, 2024…

7 months ago

Lophos Pharmaceuticals Corp. Receives Traditional Blessing for Napanee Site in Honor of Indigenous Heritage

Napanee, Ontario--(Newsfile Corp. - May 15, 2024) - Lophos Holdings Inc. (CSE: MESC) ("Lophos" or the "Company") proudly announces the…

7 months ago

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

LAVAL, QC / ACCESSWIRE / May 15, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its…

7 months ago

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA’s Potential Market

Study to evaluate clinical effectiveness of low-dose oral interferons in treating chronic gingivostomatitis in cats, building upon VELDONA's history in…

7 months ago

NanoViricides Has Filed its Quarterly Report

NV-387 Advancing to Phase II Clinical Trial for the Treatment of RSV Infection SHELTON, CT / ACCESSWIRE / May 15,…

7 months ago

Evotec SE to Announce Results for First Quarter 2024 on 22 May 2024

HAMBURG, GERMANY / ACCESSWIRE / May 15, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO)…

7 months ago

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

BOSTON and ATLANTA, May 15, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical…

7 months ago

ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update

Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR…

7 months ago